Mission Bio Partners With LabCorp to Accelerate Targeted Drug Development with Single-Cell Genomics
Product News Mar 28, 2019
The Mission Bio Tapestri® Platform
Mission Bio, the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced that it has entered into a collaboration with LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care. LabCorp’s Covance Drug Development Business will be the first global contract research organization to offer services on the Mission Bio Tapestri® Platform, supporting biopharmaceutical customers in their need for faster, more precise clinical trials. Further, LabCorp Diagnostics is evaluating the Tapestri Platform for applications in clinical diagnostics and in the development of new companion diagnostics. This collaboration follows LabCorp’s strategic investment in Mission Bio’s $30 million Series B funding round, which was completed in December 2018.
With the growing complexity of clinical trials, precision biomarkers are needed to reduce the time and costs associated with the drug development cycle. Broad-based sequencing technologies in most cases lack the sensitivity to identify the rare cells that drive disease. The Mission Bio Tapestri Platform is currently the only single-cell targeted DNA solution available to more precisely identify cancer cell mutation profiles. Tapestri’s unique ability to sensitively detect rare cancer subclones and co-occurring cancer mutations using single-cell genomics offers a precise way to measure therapy response and disease progression.
“With its leadership across drug development and diagnostics, LabCorp and the Covance Drug Development organization are the ideal partner to expand our global ecosystem by opening access to the biopharmaceutical industry,” said Charlie Silver, CEO of Mission Bio. “We have had significant interest from global pharma companies that want to access Tapestri to support their clinical programs. With this partnership, we can now offer complete support from preclinical and biomarker discovery through to clinical trials and commercialization.”
“LabCorp’s leadership in precision medicine is based on a combination of knowledge, experience, and our ability to recognize and utilize novel genomics tools that can support the development and commercialization of new therapies and diagnostics” said Steve Anderson, Ph.D., chief scientific officer of Covance Drug Development. “The Mission Bio Tapestri Platform fully supports our strategy to remain a leader in bringing these increasingly important tests to physicians and patients. There is keen interest in improving the identification of residual cancer cells that remain after treatment, to provide more specific information about treatment response and remission durability. A more sensitive test for minimal residual disease (MRD), which is possible through single-cell genomics, has great potential to streamline clinical trials and help providers manage their patients’ care more effectively.”
Separately, Mission Bio is also announcing an alliance with Argonaut Manufacturing Services, a cGMP contract manufacturing organization (CMO) serving the biopharmaceutical and human diagnostics industries, to serve as its preferred global CMO. With Argonaut’s added expertise in operations and manufacturing, Mission Bio completes its supply chain to provide customers with an end-to-end solution for its biopharmaceutical business and enables turnkey commercialization of its Tapestri Platform.